Background The coronavirus disease (COVID-19) epidemic has not been completely
controlled. Although great achievements have been made in COVID-19 research and many …

Background Molnupiravir was granted emergency use authorization for the treatment of mild
to moderate coronavirus disease 2019 (COVID-19). In this study, we used population-based …

Favipiravir is considered a potential treatment for COVID-19 due its efficacy against different
viral infections. We aimed to explore the safety and efficacy of favipiravir in treatment of …

ABSTRACT Molnupiravir (EIDD-2801/MK-4482), the prodrug of the active antiviral
ribonucleoside analog β-d-N4-hydroxycytidine (NHC; EIDD-1931), has activity against a …

Importance Diabetes and COVID-19 are both global pandemics, and type 2 diabetes is a
common comorbidity in patients with acute COVID-19 and is proven to be a key determinant …

Objective To emulate a randomized target trial to estimate the association between the
antiviral drug molnupiravir and hospital admission or death in adults with SARS-CoV-2 …

Molnupiravir is a β-d-N4-hydroxycytidine-5′-isopropyl ester (NHC) compound that exerts
antiviral activity against various RNA viruses such as influenza, SARS, and Ebola viruses …

This study aimed to compare the efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) with
molnupiravir in the treatment of coronavirus disease 2019 (COVID‐19). To end this …

The Covid-19 pandemic has resulted in substantial global morbidity and mortality as well as
disruption of the economies of virtually every country. 1 Some of this tragedy could have …

Background The real-world effectiveness of molnupiravir (MOL) during the dominance of
Omicron SARS-CoV-2 lineage is urgently needed since the available data relate to the …